



NON-RENOUNCEABLE RIGHTS ISSUE

OBJ Limited (ASX: OBJ) (**Company**) is pleased to announce that it intends to undertake a capital raising to raise up to approximately \$3.61 million (before expenses of the capital raising).

The capital raising consists of a pro-rata entitlement offer of new shares and free attaching options to the Company's existing eligible shareholders, and also a pro rata entitlement offer of new options to the Company's existing eligible option holders, the details of which are set out below.

Rights Issue Offer

The Company intends to undertake a fully underwritten non-renounceable pro rata offer of approximately 235,099,450 fully paid ordinary shares (**New Shares**) to raise approximately \$3.53 million (before expenses) (**Rights Issue Offer**).

Under the proposed Rights Issue Offer, eligible shareholders will be entitled to subscribe for one (1) New Share for every five (5) fully paid ordinary shares held at the record date, at an issue price of \$0.015 per New Share.

Subscribers of New Shares will also receive two (2) new options to acquire fully paid ordinary shares in the Company (**Attaching New Options**) for every five (5) New Shares subscribed for under the Rights Issue Offer at no additional cost. Attaching New Options issued under the Rights Issue Offer will be exercisable at \$0.01 on or before 31 December 2014. The Company will apply to ASX for quotation of the Attaching New Options.


The Company has entered into a mandate with Novus Capital Limited (**Novus Capital**) who will act as manager and underwriter for the proposed Rights Issue Offer. Underwriting by Novus Capital will be subject to formal agreement between the Company and Novus Capital on terms to be agreed.

Novus Capital will receive a fee of 1% plus GST for managing the Rights Issue Offer, and a fee of 5% plus GST for underwriting the Rights Issue Offer. Novus Capital will also be paid an advisory fee of \$35,000 plus GST. In addition to these fees, Novus Capital (or its nominee) will receive 5,000,000 options on the same terms of the Attaching New Options set out above, to be quoted on the ASX. Novus Capital will pay any sub-underwriting fees.

Option Offer

The Company also intends to undertake a non-renounceable pro rata offer to existing option holders of approximately 86,455,927 new options (**Option Offer Options**) to raise approximately \$86,455 (before expenses) (**Option Offer**).

For personal use only



Under the proposed Option Offer, eligible option holders will be entitled to subscribe for one (1) Option Offer Option for every one (1) existing option held at the record date, at an issue price of \$0.001 per Option Offer Option. The Option Offer Options will be exercisable at \$0.01 on or before 31 December 2014 and will rank equally in all respects with the Attaching New Options issued under the Rights Issue Offer. The Company will apply to ASX for quotation of the Option Offer Options.

The Option Offer is being undertaken to allow the Company's existing option holders to participate in the capital raising.

The Option Offer is not underwritten.

Use of funds

The funds raised by the Rights Issue Offer and Option Offer and the issue of shares upon the exercise of Attaching New Options and Option Offer Options will be applied by the Company to advance its own products program including the Musculoskeletal and Pain Management development (\$2.0 million), Clinical Development Programs (\$0.3 million), Intellectual Property (\$0.3 million), Technology Expansion Programs (\$0.4 million) and Working Capital (\$0.61 million).

Timetable

The Company intends to announce the final terms and timetable for the capital raising (including the record date) as soon as possible. It is intended that offers under the Rights Issue Offer and Option Offer will be made in the form of a Prospectus to be despatched to eligible shareholders together with an application form in accordance with the timetable.

- Ends -

For more information:


Mr Glyn Denison Director

P +618 9443 3011
E info@obj.com.au
W www.obj.com.au

For personal use only

OBJ Limited

leaders in magnetic micro-array drug delivery



About OBJ:

OBJ develops proprietary magnetic micro-array drug delivery and product enhancement technologies for the pharmaceutical, healthcare and consumer goods sectors.

OBJ partners companies in the design and development of next generation products using physical science rather than chemistry to provide new levels of product performance without the cost of reformulation or new ingredient approvals.

OBJ offers a portfolio of proprietary technologies and supports partners by providing IP-protected market exclusivity, expertise in magnetic array design, feasibility and efficacy and claims testing, engineering and production.

About OBJ's Technologies

OBJ has developed a platform of physical enhancement technologies based on low-cost magnetic micro-arrays that influence the movement and penetration of drugs, active ingredients and formulations at the molecular level.

Complex 3-D array and moving magnetic fields have the ability to repulse certain molecules to enhance diffusion and to alter the permeability of certain biological and non-biological targets.

OBJ develops low cost micro-array film technology that utilises diamagnetic repulsion, induced permeation and energy redirection to offer a new way of managing the speed, depth of penetration and delivery of active ingredients in a wide range of pharmaceutical and consumer products.

Forward-looking Statements

This announcement contains certain "forward-looking statements" concerning OBJ. Where OBJ expresses or implies an expectation or belief as to future events or results, such expectation or belief is expressed in good faith and believed to have a reasonable basis.

Forward-looking statements provided in this announcement are based on assumptions and contingencies which are subject to change without notice. Such forward-looking statements including statements regarding intentions, planned events and potential results are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance.

There can be no assurance that actual outcomes will not differ materially from these forward-looking statements, and there are risks associated with OBJ and the industry which may affect the accuracy of the forward-looking statements. OBJ does not undertake any obligation to release publicly any revisions to any forward looking statement to reflect events or circumstances after the date of this announcement or to reflect the occurrence of unanticipated events, except as may be required under applicable securities laws.

ABN 72 056 482 636

284 Oxford Street, Leederville 6007 Perth, Western Australia

Telephone +61 8 9443 3011 Facsimile +61 8 9443 9960

www.obj.com.au

For personal use only